This work relates the development and validation of a simple reversed-phase high-performance liquid chromatographic (HPLC) method for the analysis of xanthone (XAN) and 3-methoxyxanthone (3-MeOXAN
Introduction
Xanthones represent a large group of heterocyclic compounds including natural, semisynthetic, and totally synthetic structures (1) . Chemically, xanthonic nucleus corresponds to dibenzo-γ-pyrone. Xanthone (XAN) molecules, having a variety of substituents on the different carbons of the nucleus, constitute a group of compounds with a broad spectrum of biological activities. Among others, antitumoral (2, 3) , antibacterial (4), antiinflammatory (5), hepatoprotective (6) , antimalarial (7), immunomodulatory (8, 9) , as well as inhibitory activities of angiotensin converting enzyme (10) and monoamine oxidase (MAO) (11, 12) have been described. Xanthone itself was described as a good MAO-A inhibitor (13) .
Poor aqueous solubility of XAN and many of its derivatives such as 3-methoxyxanthone (3-MeOXAN) ( Figure 1 ) is a major obstacle for the assessment of the pharmacological activity of these compounds and their use in the therapy. In general, besides the difficulties of administration of drug substances, water insolubility is often associated with poor bioavaliability (14) .
One approach to overcome the difficulty of administration of poorly water-soluble compounds is by their incorporation in carrier systems such as polymeric microparticles and nanoparticles. The efficiency of this approach was successfully proven for different drugs (15) (16) (17) . Nanoparticles are solid submicronic drug carriers of a polymeric nature in the nanometer size (18) . According to the process used for preparation of nanoparticles, nanospheres or nanocapsules can be obtained. Nanocapsules are vesicular systems in which the drug is confined to a cavity surrounded by a polymeric membrane; nanospheres are matrix systems in which the drug is dispersed throughout the particles (19) . Besides the improvement of delivery of water-insoluble drugs, nanoparticles have afforded several advantages for different drugs such as reducing drug-associated adverse effects (19) , protecting the compound from inactivation before reaching its site of action (20) , and increasing the intracellular penetration (21) .
By incorporating XAN or its derivatives (such as 3-MeOXAN) in nanoparticles, these poorly water-soluble compounds may be administered as nanoparticle aqueous dispersions at concentrations higher than their maximum hydrosolubility. Moreover, the incorporation of these compounds in nanoparticles may also allow different ways of administration and, simultaneously, may afford their in vivo protection and targeting.
In our laboratory we routinely carry out in vitro studies with poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles containing either xanthone or xanthone derivatives in order to test the usefulness of these colloidal systems as potential carriers for this group of compounds. For this purpose, the estimation of nanoparticle content is an essential tool for guarantying the reliability of the results. The aim of this work was to develop and validate a specific, sensitive, and simple high-performance liquid chromatography (HPLC) method for the quantitative analysis of XAN and 3-MeOXAN, which were entrapped in PLGA nanocapsules for the first time. PLGA has been selected because polyesters including poly(lactic acid), poly(glycolic acid), and their copolymers such as PLGA have emerged as the most widely studied class of biodegradable polymers for pharmaceutical use because of their biocompatibility and biodegradability (22) . The procedures and parameters used for validation of the analytical method were those described in the International Conference on Harmonization (ICH) guidelines (23, 24) , which are similar to the ones established by the United States Pharmacopoeia (USP) (25) .
Experimental
Reagents and chemicals XAN, PLGA (50:50, MW 50,000-75,000), Pluronic F-68, and soybean lecithin (40% purity by thin-layer chromatography) were purchased from Sigma (Madrid, Spain). 3-MeOXAN was synthesized in our laboratory by alkaline cyclization of 2-hydroxy-2',4-dimethoxybenzophenone (26) . Myritol 318 was kindly supplied by Henkel (Lisbon, Portugal). HPLC-grade methanol and acetonitrile were obtained from Merck (Whitehouse Station, NJ). HPLCgrade water was obtained by a MilliQ system (Millipore, Billerica, MA). Other chemicals were of analytical grade.
Nanocapsule preparation and characterization
XAN and 3-MeOXAN nanocapsules of PLGA were prepared according to a modification of the interfacial polymer deposition method described by Fessi et al. (27) . Approximately 50 mg of polymer and 100 mg of soybean lecithin were briefly dissolved in 10 mL of acetone. XAN (7.2 mg) or 3-MeOXAN (16.8 mg) was dissolved in 0.6 mL of Myritol 318, and the obtained solution was added to the acetonic solution. The final solution was poured into 20 mL of an aqueous solution of pluronic F-68 (0.5%, w/v) under moderate stirring, leading to the formation of nanocapsules. Acetone was then removed under vacuum, and the colloidal dispersion of nanocapsules was concentrated to 5 mL by evaporation under reduced pressure. Nonencapsulated xanthones (XAN or 3-MeOXAN) were separated by ultrafiltration/cetrifugation using centrifugal filter devices Centricon YM-50 (Millipore).
Empty nanocapsules were prepared according to the same procedure, but omitting xanthones in the organic phase.
The mean size and polydispersity index of aqueous nanocapsule dispersions were determined by laser light scattering (Zetasizer 5000, Malvern Instruments, Worcestershire, U.K.) generating a volume-average distribution for analyzed data.
Instrumental and chromatographic conditions
HPLC analysis was performed with a Jasco liquid chromatograph (Easton, MD) equipped with a Jasco 880-PU pump and a Jasco 875-UV spectrophotometric detector. The separation was carried out on a 250-× 4.6-mm i.d. Nucleosil C 18 column (5 µm) (Macherey-Nagel, Düren, Germany). Liquid chromatography analysis was performed by isocratic elution. The mobile phase composition was methanol-water (90:10, v/v), and the flow rate was set at 1.0 mL/min. The injected volume was 20 µL, and the detection wavelength was set at 237 nm. CWS 1.7 software (DataApex, Prague, Czech Republic) managed chromatographic data.
Analysis of samples of XAN and 3-MeOXAN subjected to thermal, acid, and alkaline stress conditions was also performed by HPLC using a different system equipped with a diode-array detector. A Spectra System liquid chromatograph equipped with a Series II digital pump (Science Marketing International, Gloucester, U.K.) with diode-array UV6000LP detector (ThermoFinnigan, San Jose, CA) was used. Samples were chromatographed using the same procedure described previously, including the used column, injected volume, and detection wavelength. Chromquest for Windows NT software (ThermoFinnigan) managed chromatographic data.
Preparation of sample solutions for determination of XAN and 3-MeOXAN in nanocapsules
Sample solutions were obtained by dissolving an aliquot of XAN or 3-MeOXAN nanocapsule dispersion in acetonitrile (corresponding to a dilution of 1/1000) and subjected to HPLC analysis. Considering 100% of entrapment of xanthones in nanocapsules, the obtained sample solutions had a maximum theoretical concentration (MTC) of 1.44 and 3.36 µg/mL of XAN and 3-MeOXAN, respectively. All analyses were performed in triplicate, and the mean results are reported.
Preparation of XAN and 3-MeOXAN standard solutions
Stock standard solutions of XAN and 3-MeOXAN (50 µg/mL) were prepared in acetonitrile. XAN and 3-MeOXAN standard solutions were obtained by dilution of the respective freshly prepared stock standard solution with acetonitrile to give six different concentrations over the range of interest (0.4-2.5 µg/mL for XAN and 1.0-5.8 µg/mL for 3-MeOXAN).
Results and Discussion

Method development
The methanol-water ratio in mobile phase and flow rate were selected in order to find the best conditions for the determination and quantitation of XAN and 3-MeOXAN in nanocapsule formulations. A mobile phase of methanol-water (90:10, v/v) was selected to achieve good separation and sensitivity. A flow rate of 1.0 mL/min gave an optimal signal-to-noise ratio and a reasonable separation time. Retention times were 5.3 min for XAN and 5.8 min for 3-MeOXAN. The total time required for analysis was 7 min. The maximum absorption of both compounds in the experimental conditions was found to be 237 nm. Therefore, this wavelength was chosen for the analysis.
For preparation of sample solution of nanocapsules containing XAN or 3-MeOXAN, different solvents (acetonitrile and dichloromethane) were evaluated in order to achieve a complete dissolution of nanocapsule aqueous dispersions. Acetonitrile was found to afford a complete dissolution upon a 1000-fold dilution of aliquots of XAN or 3-MeOXAN nanocapsule dispersions.
Validation study Specificity
According to ICH guidelines, the specificity of an analytical method is the ability to assess unequivocally the analyte in the presence of components that may be expected to be present such as impurities, degradation products, excipients, etc. (23, 24) . In the present study, the specificity of the analytical method was determined either in samples subjected to stress conditions or in samples containing nanocapsule excipients (i.e., spiked with empty nanocapsules). Samples of both xanthones were subjected to thermal, acidic, and alkaline stress conditions. For the evaluation of thermal degradation, portions of XAN and 3-MeOXAN were placed in an oven at 120ºC for 2 h. Afterwards, samples were dissolved in methanol and subjected to HPLC analysis. For the evaluation of the degradation of xanthones in acidic and alkaline conditions, a known amount (1 mg) of XAN or 3-MeOXAN was mixed with 25 mL of HCl 1N or NaOH 1N, and the obtained products were stored at room temperature for 24 h. After filtration, solutions were appropriately neutralized with HCl 1N or NaOH 1N and diluted with methanol for HPLC analysis. Controls and blank preparations were also prepared and assayed. Figure 2 shows representative chromatograms of XAN (1A) and 3-MeOXAN (2A) standard solutions. Retention times were 5.3 min for XAN and 5.8 min for 3-MeOXAN. No peaks interfering with XAN or 3-MeOXAN could be detected. A peak with a retention time between 2.8 and 3.0 min, because of the solvent front, was observed. Chromatograms corresponding to xanthone samples subjected to thermal, acidic, and alkaline stress conditions are also shown in Figure 2 (1C-E and 2C-E). No interfering peaks with retention times similar to those of XAN or 3-MeOXAN were observed from any of the stressed samples. Comparison of diodearray spectra, which were obtained at the leading edge, apex, and trailing edge of the XAN and 3-MeOXAN peaks, were identical. This peak purity check, made possible by diode-array technology, is a good indication for the absence of interfering peaks.
In order to evaluate the specificity of the analytical method concerning the presence of nanocapsule excipients (i.e., the potential interference of the excipients), a comparison of the test results from the analysis of XAN and 3-MeOXAN standard solutions spiked with empty nanocapsules with those obtained from the analysis of XAN and 3-MeOXAN standard solutions alone was carried out. Obtained chromatograms (Figure 2 , 1B and 2B) show the absence of any peak in the region where xanthones elute, which indicates that the method is specific concerning to nanocapsule excipients.
Linearity and range
According to ICH guidelines, the linearity of an analytical method is its ability (within a given range) to obtain test results that are directly proportional to the concentration of analyte in the sample (23, 24) .
Linear regression analysis was carried out by plotting average peak area (y) versus analyte concentration (x) in the concentration range of 0.4-2.5 µg/mL for XAN and 1.0-5.8 µg/mL for 3-MeOXAN. Calibration curves were constructed at six concentration levels using the linear-squares regression procedure. The overall procedure was repeated three times on different days. The peak area values obtained for three replicate analyses were averaged at each concentration.
Obtained calibration curves showed to be linear over the concentration ranges examined for XAN and 3-MeOXAN, giving correlation coefficients (r) greater than 0.999 and coefficients of determination (R 2 ) greater than 0.9980 (i.e., over a 99.8% relationship between x and y) ( Table I) .
Accuracy
According to ICH guidelines, the accuracy of an analytical method expresses the closeness of agreement between the value that is accepted either as a conventional true value or an accepted reference value and the value found (23, 24) . Accuracy is often calculated as percent recovery by the assay of known, added amounts of analyte to the sample. Accuracy should be assessed using a minimum of nine determinations over a minimum of three concentration levels.
Accuracy was determined by spiking known amounts of XAN or 3-MeOXAN to aqueous dispersions of empty nanocapsules in order to obtain XAN concentrations of 0.4, 1.0, and 1.4 µg/mL (corresponding approximately to 28%, 69%, and 97% of MTC) and 3-MeOXAN concentrations of 1.0, 2.4, and 3.4 µg/mL (corresponding approximately to 30%, 71%, and 101% of MTC). Table  II summarizes the accuracy results, expressed as percent recovery and relative standard deviation (RSD). Recovery data were within the range of 99.61-102.75% (RSD = 1.18%) and 98.77-102.38% (RSD = 1.04%) for XAN and 3-MeOXAN, respectively. Overall mean recovery values were 100.69% (n= 9) for XAN and 100.89% (n = 9) for 3-MeOXAN. Because the mean recovery results were within an acceptable ± 3% range, according to Segall et al., the method was deemed to be accurate (28) .
Precision
According to ICH guidelines, the precision of an analytical method expresses the closeness of agreement between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions (23, 24) . Precision may be measured as repeatability (also termed "intraassay precision"). Repeatability expresses the precision under the same operating conditions over a short interval of time. ICH guidelines recommend that repeatability should be assessed using a minimum of nine determinations covering the specified range (i.e., three concentrations and three replicates for each concentration) or a minimum of six determinations of 100% of the test concentration.
In the present study, precision of the analytical method was determined by the analysis, on the same day, of six independently prepared standard solutions (1.4 µg/mL for XAN and 3.4 µg/mL for 3-MeOXAN), corresponding to approximately 100% of MTC. Obtained RSD values (1.09% for XAN and 1.38% for 3-MeOXAN) indicate that the proposed HPLC method shows acceptable repeatability (Table III) . These results are in agreement to the criteria proposed by Green for the precision of an analytical method, for which the RSD should be lower than 2% (29) .
Application of the developed method to the quantitative determination of XAN and of 3-MeOXAN in nanocapsules
The present validated method was used to determine either XAN or 3-MeOXAN encapsulated in different nanocapsule batches. Table IV shows encapsulation parameters and particle size of prepared PLGA nanocapsule formulations. High encapsulation efficiency values of xanthones in PLGA nanocapsules (84.1% for XAN and 81.2% for 3-MeOXAN) were obtained. The mean particle size of XAN and 3-MeOXAN nanocapsules was 231 nm and 245 nm, respectively.
Conclusion
A simple isocratic reversed-phase HPLC method was developed for the determination of XAN and 3-MeOXAN in PLGA nanocapsule formulations. The method was validated according to ICH guidelines and USP 25 for its specificity, linearity, accuracy, and precision. Results of validation showed that the proposed method is specific, linear, accurate, and precise either for XAN or 3-MeOXAN, within the established ranges.
XAN and 3-MeOXAN nanocapsule formulations were prepared for the first time. No degradation of the compounds was found upon nanocapsule preparation by the adopted interfacial polymer deposition method, and high encapsulation efficiencies were obtained. Results clearly demonstrate the suitability of this method for incorporating both poorly water-soluble compounds in PLGA nanocapsules. In vitro studies are being undertaken in different cell lines in order to test the potential of these colloidal delivery systems for xanthone and its derivatives. The presently developed and validated HPLC method was successfully used to determine either XAN or 3-MeOXAN content in nanocapsule formulations, affording a very important tool for the evaluation of the finished products. The method could also be useful for the quantitation of different xanthone derivatives encapsulated in nanocapsules. However, further validation studies should be performed for each compound.
